A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CheckMate 714
- Sponsors Bristol-Myers Squibb
- 05 Jan 2017 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
- 07 Oct 2016 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.